← Eichor
Condition: Camrelizumab Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Camrelizumab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06413992HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06333561Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05981001Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07026149Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
Phase 2 · 1 location(s) · Ying Lin · NCT05761470Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05624099Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
Phase 2 · 1 location(s) · Fudan University · NCT06516289Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06323382Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Phase 2 · 1 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT06561308Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocar
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06163729Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in P
Phase 2 · 8 location(s) · CrystalGenomics, Inc. · NCT05841472Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05613478Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT04342910Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
Phase 2 · 3 location(s) · Zhejiang Cancer Hospital · NCT05507411Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma
Phase 2 · 8 location(s) · Qian Chu · NCT04888429A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT05182944Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the
Phase 2 · 1 location(s) · yue junhan · NCT06176885Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06669611Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cyc
Phase 3 · 1 location(s) · Fudan University · NCT05772208Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT05825443Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast
Phase 3 · 7 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06889688Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy fo
Phase 2 · 1 location(s) · The First Affiliated Hospital of Henan University of Science · NCT07622797A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Meng Chao Hepatobiliary Hospital of Fujian Medical Universit · NCT05409482Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Phase 2 · 1 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT07167160Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Phase 2 · 1 location(s) · Shandong Tumor Hospital · NCT07320586Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carci
Phase 2 · 1 location(s) · West China Hospital · NCT06831175TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
NA · 1 location(s) · Sun Yat-sen University · NCT06622031Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06121557RFA Plus Carrizumab vs Carrizumab Alone for HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT04150744A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and
Phase 2/Phase 3 · 2 location(s) · Hutchmed · NCT06361888
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.